Your Article Summary
See Latest ArticlesFDA drug approval summary: nelarabine for the treatment of T-Cell lymphoblastic leukemia/lymphoma
The Oncologist, 07/03/08
Cohen MH et al. - In a study to describe the clinical trials leading to FDA approval of nelarabine for the treatment of pts with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens, on October 28, 2005, the FDA granted accelerated approval for nelarabine for treatment of pts with relapsed or refractory T-ALL/T-LBL after at least 2 prior regimens
Methods- 2 phase II trials, 1 conducted in pediatric pts and the other in adult pts, were reviewed
- Pts were in their first or subsequent relapse and/or were refractory to first-line therapy
- The dose and schedule of i.v. nelarabine in the pediatric and adult studies were 650 mg/m2 per day daily for 5 days and 1500 mg/m2 i.v. on days 1, 3, and 5, respectively
- Treatments were repeated every 21 days
- Study endpoints were the rates of complete response (CR) and CR with incomplete hematologic or bone marrow recovery (CR*)
- Pediatric efficacy population consisted of 39 pts who had relapsed after, or had been refractory to, 2 or more induction regimens
- CR to nelarabine treatment was observed in 5 pts and CR+CR* was observed in 9 pts
- The adult efficacy population consisted of 28 pts
- CR to nelarabine treatment was observed in 5 patients and CR+CR* was observed in 6 pts
Related Articles
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics and outcome from the large randomised prospective trial (UKALL XII/ECOG 2993)
Blood, 11/02/09
Relevance Score: 79%
Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin–Frankfurt–Münster (BFM) protocols containing early and late re-intensification elements
British Journal of Haematology, 10/16/09
Relevance Score: 78%
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
British Journal of Haematology, 11/04/09
Relevance Score: 67%
Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211
Journal of Clinical Oncology, 10/12/09
Relevance Score: 66%
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
Journal of Clinical Oncology, 10/09/09
Relevance Score: 66%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
microRNAs in acute myeloid leukemia: Expression patterns, correlations with genetic and clinical parameters, and prognostic significance
Genes, Chromosomes and Cancer, 12/19/09
Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia
Genes, Chromosomes and Cancer, 12/19/09
C/EBPbeta expression in ALK+ anaplastic large cell lymphomas (ALCL) is required for cell proliferation and is induced by the STAT3 signaling pathway
Haematologica, 12/18/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/18/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/18/09